Published in
Public Library of Science, PLoS ONE, 6(10), p. e0126882, 2015
DOI: 10.1371/journal.pone.0126882
Links
- ORCID
- Public Library of Science
- [vbn.aau.dk]
- [www.ncbi.nlm.nih.gov] | PDF
- [journals.plos.org] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study)
Journal article published in 2015 by
Christian Daugaard Peters 
,
Krista Dybtved Kjaergaard,
Jens Dam Jensen,
Kent Lodberg Christensen,
Charlotte Strandhave,
Ida Noerager Tietze,
Marija Kristina Novosel,
Bo Martin Bibby,
Bente Jespersen
,
Krista Dybtved Kjaergaard,
Jens Dam Jensen,
Kent Lodberg Christensen,
Charlotte Strandhave,
Ida Noerager Tietze,
Marija Kristina Novosel,
Bo Martin Bibby,
Bente Jespersen
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
BACKGROUND AND AIM: Little is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan. DESIGN: Randomized, double-blind, placebo-controlled, one-year intervention trial. SETTING AND PARTICIPANTS: Eighty-two hemodialysis patients with urine output >300 mL/day and dialysis vintage